| scholarly article | Q13442814 |
| P2093 | author name string | Lazarus HM | |
| Gupta V | |||
| Keating A | |||
| P2860 | cites work | Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | Q28209814 |
| Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation | Q28277744 | ||
| Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission | Q28290182 | ||
| Marrow Transplantation for Acute Nonlymphoblastic Leukemia in First Remission | Q28305230 | ||
| A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation | Q31536804 | ||
| Is there a best transplant conditioning regimen for acute myeloid leukemia? | Q33864598 | ||
| Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation | Q34186689 | ||
| Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century | Q34327318 | ||
| The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation | Q34446665 | ||
| The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial | Q34525604 | ||
| Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review | Q35071096 | ||
| Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects | Q40706569 | ||
| Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first compl | Q43629955 | ||
| Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia | Q43666936 | ||
| Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study | Q43684700 | ||
| Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation | Q43742785 | ||
| Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant | Q43770761 | ||
| Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. | Q43817807 | ||
| Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies | Q43819615 | ||
| Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. | Q43947438 | ||
| Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. | Q44117655 | ||
| Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes | Q44175621 | ||
| Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100- | Q44175627 | ||
| Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation | Q44198535 | ||
| Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission | Q44242611 | ||
| A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning | Q44245108 | ||
| Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission | Q44287669 | ||
| Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation | Q44938646 | ||
| Solid cancers after bone marrow transplantation | Q48760643 | ||
| Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide | Q52873579 | ||
| High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients | Q58789383 | ||
| Bone marrow transplantation in the busulfan-treated rat. II. Effect of cyclophosphamide and antithymic serum on the presensitized state | Q67512361 | ||
| Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia | Q69532019 | ||
| A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for B | Q71127546 | ||
| Risk factors in interstitial pneumonitis following allogenic bone marrow transplantation | Q71454499 | ||
| Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad | Q72377470 | ||
| Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle | Q72504244 | ||
| Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia | Q73104276 | ||
| Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study | Q73171815 | ||
| Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation | Q73737109 | ||
| An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children | Q73810014 | ||
| High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation | Q77163082 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 969-978 | |
| P577 | publication date | 2003-11-01 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Myeloablative conditioning regimens for AML allografts: 30 years later | |
| P478 | volume | 32 |
| Q47135533 | Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India |
| Q37370649 | Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. |
| Q42060470 | Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations |
| Q35085078 | Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation |
| Q38217938 | Complications of allogeneic hematopoietic stem cell transplantation |
| Q46981168 | Different behavior of SCE-eliciting lesions induced by low and high doses of busulfan |
| Q41189360 | Effectiveness of fludarabine- and busulfan-based conditioning regimens in patients with acute myeloblastic leukemia: 8-year experience in a single center |
| Q46485581 | Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. |
| Q36065763 | Hematologic aspects of myeloablative therapy and bone marrow transplantation. |
| Q38690071 | Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report |
| Q53628874 | Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin. |
| Q45233938 | High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia |
| Q45001844 | High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation |
| Q35784905 | Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. |
| Q57794882 | Improving hematopoietic recovery through modeling and modulation of the mesenchymal stromal cell secretome |
| Q26853490 | Management of patients with hepatitis B who require immunosuppressive therapy |
| Q40190932 | Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. |
| Q38301003 | Reduced adiposity in ob/ob mice following total body irradiation and bone marrow transplantation |
| Q46715697 | Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment |
| Q34463645 | Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies |
| Q44043143 | The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison |
Search more.